A study of Bosulif for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study watches how well the medicine Bosulif works for adults with chronic myeloid leukemia in everyday medical practice. You can join if you’re already taking Bosulif or starting it soon, as long as you started within the last year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with chronic myeloid leukemia.
- You are currently taking Bosulif (bosutinib) or will start it soon, as part of your regular care.
- You started taking Bosulif within the past year.
- You are willing to sign a form allowing Pfizer to use your health information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called bosmolisib for people with peripheral T-cell lymphoma (PTCL) that has come back or not responded to standard treatments. The goal is to see if this drug can help shrink tumors and control the disease.
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
This study looks at how well your blood vessels work (“vasoregulation”) in people with chronic myeloid leukemia (CML) while taking bosutinib. The goal is to understand vascular changes and how they relate to treatment in CML.
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Hear when a new Chronic Leukemia Myelogenous trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.